Led · Series B · Jul 2026

Epitel develops the REMI Remote EEG Monitoring System, a wireless, wearable EEG platform designed to enable extended-duration brain monitoring at home for days to weeks. The REMI portfolio has received five U.S. FDA 510(k) clearances across its wireless EEG monitoring and AI-driven event detection technologies. REMI Vigilenz AI analyzes REMI EEG to flag potential seizures and is cleared for use in patients aged six and older, while the overall platform is cleared for patients as young as one year. Epitel is initially focused on seizure detection and diagnosis and cites gaps in access—noting 9.2 million Americans experience seizures annually while many lack EEG access. The company says its technology aims to improve clinician workflow by accelerating capture of objective seizure evidence and to broaden access to neurological care outside traditional hospital settings. With the recently closed Series B, Epitel plans to expand its commercial infrastructure and field team to accelerate adoption and market penetration.

Participated · Series C · Jun 2026

Rejoni is focused on developing and commercializing gynecological products built on proprietary biomaterials, with its lead investigational product the Juveena Hydrogel System. Juveena is designed to reduce the incidence and severity of intrauterine adhesions by placing a temporary hydrogel spacer in the uterine cavity using a proprietary transcervical catheter. The product is investigational and pending U.S. FDA approval and is not available for sale. Rejoni is clinical-stage and plans to scale manufacturing, supply operations, and market-access and physician/patient engagement in preparation for commercial launch. The company was founded in June 2020 in Bedford, MA; Amar Sawhney is founder and chairman and John Nealon is CEO. The recent $25 million financing will support these commercialization and regulatory preparations.

Led · Series B · Sep 2024

Venova Medical is developing the velocity percutaneous arteriovenous fistula (pAVF) system to create AVFs for hemodialysis access. The velocity system is designed to reduce the need for reinterventions to achieve fistula maturation, improve vascular access outcomes, and lower costs. The company is conducting the prospective, single-center, single-arm VENOS-1 clinical trial (NCT05757726) evaluating the safety and feasibility of the velocity system in patients on hemodialysis. Venova intends to use new funding to support clinical studies of the velocity pAVF system in patients with chronic and end-stage renal disease. The company was co-founded by CEO Erik van der Burg and Shant Vartanian, MD, and recently appointed Darshana Zaveri of Catalyst Health Ventures to its board. Venova is based in Los Gatos, California.

Participated · Series B · May 2024

Brixton Biosciences is a clinical-stage life sciences company developing Neural Ice, an injectable, drug-free pain management technology intended to provide long-lasting relief from chronic and post-operative pain. The company is refining Neural Ice and intends to accelerate its clinical application, expanding development beyond its initial study focused on chronic knee pain. Neural Ice is positioned as a non-pharmacological alternative aimed at reducing reliance on opioids and addressing aspects of the opioid crisis. Brixton recently received first-year funding of a $2 million grant (R44AR084998) from the NIH HEAL Initiative to support its development work. The award is intended to enable further development and clinical advancement of Neural Ice across additional indications. Sameer Sabir, CEO and co-founder, characterized the grant as a significant step toward bringing safer, non-addictive pain options to a broad array of patients. Brixton Biosciences is a Cambridge, MA-based clinical-stage life sciences company spun out of Massachusetts General Brigham and led by CEO Sameer Sabir. Its lead therapeutic approach, Neural Ice™, is a single, safe, drug-free injectable designed to provide locally targeted, non-addictive, and comparatively long-lasting pain relief. The company plans to use new capital to initiate pivotal clinical studies in both chronic and acute pain indications. Specifically, Brixton will pursue two pivotal studies to treat knee pain associated with osteoarthritis and pain from knee replacement surgery. Management says the firm intends to expand the Neural Ice platform beyond the knee to multiple pain indications with an ultra-long acting injectable nerve block. The company recently added Dr. Michael Fishman as Chief Medical Officer and appointed Reggie Groves to its board to support clinical and commercial efforts.

Participated · Series C · Apr 2024

AtaCor Medical is a San Clemente, CA-based medical device company advancing extravascular cardiac rhythm management technology. Its core products include a proprietary extravascular temporary pacing lead system and a third-generation EV-ICD lead. The company’s technology aims to provide benefits of traditional transvenous implantable cardiac defibrillation and temporary pacing without placing leads or devices in the heart or vascular system, preserving the heart for future care. AtaCor plans to use the new financing to support an FDA submission for its extravascular temporary pacing lead and to complete a pilot study for the third-generation EV-ICD lead system. Led by CEO Rick Sanghera, management says the investment will advance clinical and regulatory milestones. The company is positioning its novel products to bring them to patients. AtaCor Medical is developing a novel extracardiac pacing system designed to provide cardiac pacing without placing hardware on or inside the heart. The extracardiac lead is intended to be inserted without medical imaging, avoids vascular access, and leaves the heart untouched. The design aims to eliminate bedrest restrictions associated with temporary pacing and to improve patient mobility and post-procedural recovery. The technology has completed early clinical evaluation and the company is developing the system for both temporary and permanent pacing markets. AtaCor plans to use new funding to finish development, build additional clinical evidence, and pursue US and EU regulatory clearances. The company was established in 2014, its management team has over 80 years of combined experience, and the extracardiac pacing system is not yet approved for sale in any geography. AtaCor Medical is developing a novel extravascular substernal cardiac pacing system that requires no hardware to be placed inside or onto the patient’s heart. The substernal lead is inserted without the need for medical imaging, avoids vascular access, and leaves the heart untouched. The design aims to eliminate bedrest restrictions associated with temporary pacing and to improve post-procedural mobility and recovery. The technology is being developed for both temporary and permanent pacing markets and targets treatment of transient and chronic bradycardia, including temporary pacing needs tied to TAVR procedures. The company is not yet approved for sale in any geography. The $8.8M Series A financing will support continued development efforts. AtaCor was established in 2014 and is based in San Clemente, California; its management team brings over 80 years of combined experience in implantable cardiac devices and electrophysiology.